The Weekly Recap 10/3/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

 In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure new funding, achieve clinical and regulatory milestones, and much more on the road to LSI USA ‘26 in Dana Point (March 16–20).

Adagio Medical

Completed enrollment of the FULCRUM-VT pivotal FDA IDE study evaluating its ventricular tachycardia-specific ablation technology, with 208 patients across 20 centers. Adagio’s vCLAS™ Cryoablation System, which uses proprietary ultra-low temperature cryoablation (ULTC) technology, is being evaluated to support FDA pre-market approval for the treatment of monomorphic ventricular tachycardia.

AiM Medical Robotics

Raised $8.1M in Series A funding to advance its MRI-compatible surgical robotics platform for neurosurgery applications. The company will use the proceeds to fund its first-in-human clinical study, expand strategic partnerships, and accelerate product development and regulatory progress.

CorWave

Reported encouraging first patient results from its first-in-human study evaluating the CorWave LVAS for advanced heart failure. The membrane-based device demonstrated full circulatory support with preserved physiologic pulsatility and no device-related adverse events at 30 days, supporting its potential to reduce complications and improve patient outcomes.

Cyber Surgery

Launched ALAYA, the first CE-certified surgical robotic assistant for spine procedures with patented Kinematic Navigation Technology. Cyber Surgery’s debut product delivers continuous tracking, faster setup, and reduced radiation exposure, marking a significant milestone for European surgical robotics and advancing the company’s commercialization and international growth.

DeepSight Technology

Appointed Dr. Bradford Wood as Vice President of Strategic Partnerships, bringing decades of leadership in interventional radiology, interventional oncology, and image-guided minimally invasive therapies to DeepSight. The interventional imaging pioneer joins DeepSight to accelerate the adoption of its NeedleVue™ systems and expand strategic collaborations across hospitals, research institutions, and industry partners.

DermaSensor

Raised $16M in Series B funding to accelerate the commercial expansion of its FDA-cleared, AI-powered skin cancer detection technology. The handheld spectroscopy platform has scanned over 20,000 lesions since mid-2024 and will support pipeline programs and clinical validation efforts following pivotal data showing it halves missed skin cancer rates.

Distalmotion

Received a third FDA clearance for the DEXTERⓇ Robotic Surgery System, expanding its U.S. indications to include total benign hysterectomy and other gynecologic procedures. The clearance reflects growing demand for outpatient robotic solutions and builds upon prior FDA clearances for inguinal hernia repair and cholecystectomy.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-weekly-recap-10325-lsi-alumni-achievements-driving-medtech-and-healthtech-forward

Comments

Post a Comment

Popular posts from this blog

Cover Story: A Page from Ray Cohen’s Playbook: Scaling, Exiting, and Winning in Medtech

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...
Read more

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more